[go: up one dir, main page]

AR086398A1 - Canabinoides que pueden usarse en el tratamiento del dolor neuropatico - Google Patents

Canabinoides que pueden usarse en el tratamiento del dolor neuropatico

Info

Publication number
AR086398A1
AR086398A1 ARP120101707A ARP120101707A AR086398A1 AR 086398 A1 AR086398 A1 AR 086398A1 AR P120101707 A ARP120101707 A AR P120101707A AR P120101707 A ARP120101707 A AR P120101707A AR 086398 A1 AR086398 A1 AR 086398A1
Authority
AR
Argentina
Prior art keywords
neuropathic pain
canabinoids
treatment
phytocannabinoids
cannabidivarine
Prior art date
Application number
ARP120101707A
Other languages
English (en)
Inventor
Geoffrey Guy
Francesco Rossi
Tetsuro Kikuchi
Colin Stott
Sabatino Maione
Original Assignee
Gw Pharma Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Ltd, Otsuka Pharma Co Ltd filed Critical Gw Pharma Ltd
Publication of AR086398A1 publication Critical patent/AR086398A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Diversos canabinoides que pueden usarse para tratar el dolor neuropático, que preferiblemente son uno o más fitocanabinoides, tales como el canabigerol (CBG), el canabicromeno (CBC), la canabidivarina (CBDV) o la tetrahidrocanabivarina (THCV), y más preferiblemente son fitocanabinoides que han sido aislados y/o purificados a partir de extractos de plantas de Cannabis.
ARP120101707A 2011-05-20 2012-05-14 Canabinoides que pueden usarse en el tratamiento del dolor neuropatico AR086398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1108506.5A GB2491118B (en) 2011-05-20 2011-05-20 Cannabinoids for use in the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
AR086398A1 true AR086398A1 (es) 2013-12-11

Family

ID=44279366

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101707A AR086398A1 (es) 2011-05-20 2012-05-14 Canabinoides que pueden usarse en el tratamiento del dolor neuropatico

Country Status (22)

Country Link
US (1) US9895342B2 (es)
EP (1) EP2709604B1 (es)
JP (1) JP6147249B2 (es)
KR (1) KR20140037124A (es)
CN (1) CN103533930A (es)
AR (1) AR086398A1 (es)
AU (1) AU2012260611B2 (es)
BR (1) BR112013029773A2 (es)
CA (1) CA2833099C (es)
CO (1) CO6811867A2 (es)
DK (1) DK2709604T3 (es)
EA (1) EA201391733A1 (es)
ES (1) ES2624308T3 (es)
GB (2) GB2491118B (es)
IL (1) IL229474B (es)
MX (1) MX2013013141A (es)
PH (1) PH12013502148A1 (es)
PT (1) PT2709604T (es)
SG (1) SG194839A1 (es)
TW (1) TW201249425A (es)
WO (1) WO2012160358A1 (es)
ZA (1) ZA201309364B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
AU2017260706B2 (en) 2016-05-04 2023-05-11 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CN109475586A (zh) 2016-06-29 2019-03-15 康纳塞斯创新公司 脱羧的大麻树脂、其用途和制备其的方法
WO2018071452A1 (en) * 2016-10-11 2018-04-19 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018236957A1 (en) * 2017-06-20 2018-12-27 Nexien Biopharma, Inc. METHOD AND COMPOSITIONS FOR TREATING REST-FREE LEG SYNDROME
CN109498606A (zh) 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
EP3684353A4 (en) 2017-09-22 2021-06-23 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US12458906B2 (en) 2018-01-23 2025-11-04 High Sierra Technologies, Inc. Methods of modifying a naturally occurring cannabis raw plant material, a purified cannabis product from a naturally occurring cannabis raw plant material, and a modified cannabis product from a naturally occurring cannabis raw plant material
US10737198B2 (en) 2018-01-23 2020-08-11 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US12178797B2 (en) 2019-05-03 2024-12-31 Zyus Life Sciences Inc. Formulation for pain management
JP2022523885A (ja) * 2019-05-03 2022-04-26 ジュス・ライフ・サイエンシーズ・インコーポレイテッド 疼痛管理のための製剤
US12220396B2 (en) 2019-05-03 2025-02-11 Zyus Life Sciences Inc. Formulation for pain management
WO2021212209A1 (en) * 2020-04-24 2021-10-28 Zyus Life Sciences Inc. Cannabichromene formulation for pain management
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4243796A4 (en) 2020-11-16 2025-01-22 Orcosa Inc. IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
WO2022218382A1 (zh) * 2021-04-14 2022-10-20 成都百裕制药股份有限公司 氘代苯酚衍生物及其制备方法和用途
WO2025091116A1 (en) * 2023-11-02 2025-05-08 Zyus Life Sciences Inc. Treatment and prophylaxis of migraine
EP4595958A1 (en) * 2024-01-29 2025-08-06 Panaxia Pharmaceutical Industries Ltd. Cannabis compositions enriched with cbca/cbc for consistent pain relief

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332039A (en) 1996-03-25 2000-06-23 Lilly Co Eli Method for treating pain using olanzapine and NSAIDs
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
GB2381194A (en) * 2001-09-07 2003-04-30 Gw Pharmaceuticals Ltd Pharmaceutical formulations
GB2377633A (en) * 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
CA2438097C (en) * 2001-02-14 2006-04-25 Gw Pharma Limited Cannabinoids pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
PT1243262E (pt) 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
PT2314284T (pt) 2002-08-14 2017-05-25 Gw Pharma Ltd Formulações líquidas de canabinoide para administração mucosal
GB2391865B (en) 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
GB0222077D0 (en) * 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
EP1747786A3 (en) 2005-07-25 2007-04-25 Perdix Eurogroup S.L. Natural product in cream with anti-vitiligo therapeutic properties
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
CA2517313A1 (en) * 2005-08-26 2007-02-26 Queen's University At Kingston Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
GB2432312A (en) 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors

Also Published As

Publication number Publication date
EP2709604A1 (en) 2014-03-26
GB201108506D0 (en) 2011-07-06
GB2524689A (en) 2015-09-30
IL229474B (en) 2018-11-29
IL229474A0 (en) 2014-01-30
JP2014513715A (ja) 2014-06-05
WO2012160358A1 (en) 2012-11-29
MX2013013141A (es) 2014-02-17
AU2012260611B2 (en) 2017-06-15
CA2833099A1 (en) 2012-11-29
PH12013502148A1 (en) 2014-01-06
US20140378539A9 (en) 2014-12-25
GB2491118B (en) 2015-12-30
GB2524689B (en) 2016-01-27
JP6147249B2 (ja) 2017-06-14
SG194839A1 (en) 2013-12-30
DK2709604T3 (en) 2017-05-15
CN103533930A (zh) 2014-01-22
ZA201309364B (en) 2015-04-29
AU2012260611A1 (en) 2013-12-12
EA201391733A1 (ru) 2014-04-30
GB201512357D0 (en) 2015-08-19
TW201249425A (en) 2012-12-16
CA2833099C (en) 2020-11-03
CO6811867A2 (es) 2013-12-16
US9895342B2 (en) 2018-02-20
NZ618246A (en) 2016-01-29
BR112013029773A2 (pt) 2017-01-17
ES2624308T3 (es) 2017-07-13
EP2709604B1 (en) 2017-02-01
GB2491118A (en) 2012-11-28
PT2709604T (pt) 2017-05-17
KR20140037124A (ko) 2014-03-26
US20140107192A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
AR086398A1 (es) Canabinoides que pueden usarse en el tratamiento del dolor neuropatico
AR088047A1 (es) Composicion farmaceutica que comprende a los fitocannabinoides cannabidivarina (cbdv) y cannabidiol (cbd)
CO6280445A2 (es) Composicion que comprende un cladosporium y un portador para las esporas
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
MX2019008337A (es) Uso de cannabinoides para el tratamiento de epilepsia.
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
EA201290975A8 (ru) Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии
MX364633B (es) Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético.
MX2021010033A (es) Composiciones microencapsuladas de cannabinoides.
BR112017010591A2 (pt) método para a preparação de uma fibra de viscose, e, fibra de viscose
UY35210A (es) Inhibidores de autotaxina
NZ629136A (en) Phytocannabinoids in the treatment of cancer
GB2492487A8 (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
MX2020001835A (es) Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.
CL2014003225A1 (es) Composición que comprende un agente de control biológico y un fungicida.
GT201400101A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
GB201120067D0 (en) Phytocannabinoids for use in the treatment of intestinal inflammatory diseases
AR089155A1 (es) Unidad de procesamiento de isomerizacion y transalquilacion de xileno combinada
CO6710926A2 (es) Compuestos de n-heteroarilo
DOP2014000253A (es) Inhibidores del nampt
MX2014005765A (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos.
CL2014000172A1 (es) Composicion en spray que comprende a) un portador de oxigeno, tal como hemoglobina o mioglobina; y b) al menos un ingrediente adicional; metodo para preparar la composicion; proceso para purificar un portador de oxigeno; y su uso para el tratamiento externo de heridas.
MX376183B (es) Composiciones para el tratamiento de rosacea.
BR112013002832A2 (pt) composição compreendendo retinol, um precursor ou um produto de reação do mesmo e um extrato vegetal de pelo menos uma planta de camomila para o tratamento de câncer
AR087879A1 (es) Composiciones para el tratamiento de ulceras perifericas de diversos origenes

Legal Events

Date Code Title Description
FB Suspension of granting procedure